Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52,942,731
-
Total 13F shares
-
38,959,310
-
Share change
-
-524,370
-
Total reported value
-
$58,833,243
-
Put/Call ratio
-
125%
-
Price per share
-
$1.51
-
Number of holders
-
70
-
Value change
-
-$767,789
-
Number of buys
-
18
-
Number of sells
-
40
Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q4 2024
As of 31 Dec 2024,
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
38,959,310 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Sio Capital Management, LLC, ArrowMark Colorado Holdings LLC, BML Capital Management, LLC, Euclidean Capital LLC, ALKEON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PFM Health Sciences, LP, ACADIAN ASSET MANAGEMENT LLC, and BlackRock, Inc..
This page lists
70
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.